Graft-Versus-Host Disease
What is Graft-Versus-Host Disease?
Graft-versus-host disease, or GVHD, is a complication that can happen after a bone marrow or stem cell transplant. It occurs when immune cells from the donor tissue attack the transplant recipient's own body. The donor cells see the recipient's tissues as foreign invaders and mount an immune response against them.
GVHD can be acute or chronic. Acute GVHD usually appears within the first 100 days after transplant. Chronic GVHD develops later and can last for months or years. The condition ranges from mild to severe and can affect multiple organs including skin, liver, digestive tract, and lungs.
While GVHD is a serious condition, it also has a potential benefit. The same donor cells that attack the recipient's tissues may also attack any remaining cancer cells. This is called the graft-versus-tumor effect. Doctors work to balance preventing GVHD while preserving this beneficial effect.
Symptoms
- Skin rash, redness, or blistering that may cover large areas of the body
- Nausea, vomiting, or loss of appetite
- Diarrhea, sometimes severe or bloody
- Abdominal cramping or pain
- Jaundice, which is yellowing of the skin or eyes
- Dry, irritated eyes or increased sensitivity to light
- Dry mouth or mouth sores
- Shortness of breath or wheezing
- Fever without other obvious cause
- Joint stiffness or muscle weakness
Some people experience mild symptoms that resolve quickly. Others develop severe GVHD that requires aggressive treatment. Symptoms vary widely depending on which organs are affected and whether the disease is acute or chronic.
Concerned about Graft-Versus-Host Disease? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
GVHD happens when donor immune cells called T-cells recognize the recipient's body as foreign. This occurs because everyone has unique proteins on their cells called human leukocyte antigens, or HLA. Even when donors and recipients are carefully matched for HLA markers, small differences can trigger an immune response. The risk increases when the donor and recipient are less closely matched.
Several factors increase the risk of developing GVHD. Using an unrelated donor rather than a sibling increases risk. Older age in either the donor or recipient raises the likelihood. Using donor cells from someone of a different sex also increases risk. Receiving a larger number of T-cells in the transplant can trigger more severe GVHD. The type of transplant preparation and the condition being treated also play a role in risk.
How it's diagnosed
Doctors diagnose GVHD based on symptoms, physical examination, and timing after transplant. A tissue biopsy from affected organs like skin, liver, or intestine can confirm the diagnosis. Blood tests help monitor disease activity and rule out other causes of symptoms like infection.
Specialized blood tests can detect markers of immune system activation. The Interleukin-2 Receptor Alpha Chain, also called IL-2Ra or CD25, is a protein released when T-cells become activated. High levels suggest active GVHD. While this specialized testing may not be part of routine blood work, your transplant team will monitor you closely with appropriate tests. Talk to your doctor about which monitoring approach is right for your situation.
Treatment options
- Immunosuppressive medications to calm the donor immune cells and reduce inflammation
- Corticosteroids like prednisone or methylprednisolone as first-line therapy
- Skin care with gentle moisturizers and sun protection for skin GVHD
- Dietary modifications including easy-to-digest foods for digestive symptoms
- Eye drops or artificial tears for dry or irritated eyes
- Physical therapy to maintain joint mobility and muscle strength
- Infection prevention measures since immunosuppressive drugs increase infection risk
- Regular monitoring with blood tests and clinic visits to adjust treatment
- Second-line treatments like ruxolitinib, ibrutinib, or phototherapy for resistant cases
- Supportive care to manage pain, nutrition, and quality of life
Frequently asked questions
Anyone who receives a bone marrow or stem cell transplant can develop GVHD. Risk is highest when the donor is unrelated or less closely matched for tissue type. Older patients and those receiving cells from donors of a different sex face higher risk. Between 30 and 70 percent of transplant recipients develop some degree of GVHD.
Acute GVHD typically develops within the first 100 days after transplant, often appearing 2 to 4 weeks post-procedure. Chronic GVHD usually starts more than 100 days after transplant but can begin earlier. Some patients develop chronic GVHD that continues from acute disease, while others have a gap between the two forms.
Yes, doctors use several strategies to prevent GVHD. Immunosuppressive medications started before or right after transplant reduce risk. Removing some T-cells from the donor cells before transplant can help. Careful matching of donor and recipient tissue types also lowers the chance of severe GVHD.
The most commonly affected organs are skin, liver, and the digestive tract including mouth, stomach, and intestines. Chronic GVHD can also affect eyes, lungs, joints, muscles, and connective tissue. Some patients experience GVHD in just one organ while others have multiple organs involved.
GVHD can be life-threatening, particularly severe acute GVHD affecting multiple organs. The condition itself and the immunosuppressive drugs used to treat it both increase infection risk. With modern treatment approaches, many patients successfully manage GVHD. Close medical monitoring and prompt treatment of complications are essential.
In transplant rejection, the recipient's immune system attacks the donated organ or cells. In GVHD, the opposite happens. The donor's immune cells attack the recipient's body. Both involve immune system reactions but they move in opposite directions.
Blood tests for liver enzymes help detect liver involvement. Complete blood counts monitor overall health and infection risk. Specialized tests like soluble IL-2 receptor alpha chain measure immune activation. Your transplant team will order a combination of routine and specialized tests based on your symptoms and organs affected.
Many people with mild to moderate chronic GVHD manage their condition and maintain good quality of life. Treatment helps control symptoms and prevent progression. Some patients need ongoing medication and lifestyle adjustments. Regular medical care, physical therapy, and attention to nutrition and infection prevention all support better outcomes.
Protecting skin from sun exposure prevents damage and reduces skin GVHD flares. Eating smaller, more frequent meals helps when digestive symptoms are present. Gentle exercise maintains mobility and prevents muscle loss. Avoiding infection through good hand hygiene and staying away from sick contacts is critical since immunosuppressive medications reduce immune defenses.
Contact your transplant team immediately if you develop new skin rashes, yellowing of skin or eyes, or increased diarrhea. Fever, severe abdominal pain, or difficulty breathing require urgent attention. Any new or worsening symptoms after transplant should be evaluated promptly since early treatment improves outcomes.